[go: up one dir, main page]

WO1998008969A1 - Molecule accessoire soluble du recepteur de l'interleukine 1 - Google Patents

Molecule accessoire soluble du recepteur de l'interleukine 1 Download PDF

Info

Publication number
WO1998008969A1
WO1998008969A1 PCT/US1996/013954 US9613954W WO9808969A1 WO 1998008969 A1 WO1998008969 A1 WO 1998008969A1 US 9613954 W US9613954 W US 9613954W WO 9808969 A1 WO9808969 A1 WO 9808969A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
acm
polypeptide
amino acid
sequence
Prior art date
Application number
PCT/US1996/013954
Other languages
English (en)
Inventor
Daniel P. Bednarik
Henrik S. Olsen
Craig A. Rosen
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Priority to AU70116/96A priority Critical patent/AU7011696A/en
Priority to PCT/US1996/013954 priority patent/WO1998008969A1/fr
Publication of WO1998008969A1 publication Critical patent/WO1998008969A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel soluble Interleukin-1 receptor accessory molecule (IL-IR AcM).
  • IL-IR AcM is a member of the Ig superfamily by analysis of its putative extracellular domain and bears limited homology throughout the protein to both Type I and Type II IL-1 receptors. More specifically, isolated nucleic acid molecules are provided encoding a human microvascular endothelial-derived soluble IL-IR AcM. The IL-IR AcM polypeptides are also provided.
  • the present invention further relates to screening methods for putative agonists and antagonists of IL-1 signal transduction.
  • Interleukin 1 is a polypeptide cytokine with multiple diverse effects on immunological and inflammatory processes. While many of the roles of IL-1 in inflammation and the immune response have been well characterized, the molecular basis of these responses remains unclear (reviewed by Dinarello,
  • IL-1 is produced by a diversity of cell types and elicits a wide variety of physiological effects in he atopoetic and nonhematopoetic cells.
  • IL-1 has biological effects on hematopoietic cells, the digestive tract, bone, cartilage and connective tissue, vascular cells, the skin, the endocrine system, the gonads, and on neural tissue.
  • IL-1 is produced by malignant cells. (Pimentel, Handbook of Growth Factors: Volume III Hematopoietic Growth Factors and Cytokines, pp. 35-53, CRC Press, Boca Raton, FL 1994).
  • the IL-1 family of proteins comprises three members: IL-l ⁇ and IL-1 ⁇ (capable of inducing IL-1 biological responses) and IL-lra (a pure receptor antagonist). These ligands bind to two distinct and separate receptors: the Type I and Type II IL-1 receptors (IL-IRs).
  • the 80-kD Type I IL-IR is found mainly on T cells and fibroblasts (Sims, J.E., et al , Science 247:585-589 (1988); Chizzonite, R., et al , Proc Natl Acad Sci USA 86 8029-8033 (1989); Sims, J.E., etal., Proc. Natl.
  • Type I IL-1 R has a cytoplasmic tail of approximately 200 ammo acids, while the Type II
  • IL-IR cytoplasmic tail is only 29 amino acids
  • the agonists IL-l ⁇ and IL-l ⁇ bind to the extracellular domains of both receptors, although with different affinities (reviewed in Dower et al , Cellular and Molecular Mechanisms of Inflammation, pp. 137-172, Academic Press, Orlando FL )
  • the relative importance of the Type I and Type II IL-IRs in IL-1 signaling has been recently clarified.
  • a critical role for the Type I IL-IR in IL-1- induced activation of NF- ⁇ B, IL-6, and IL-8 secretion, and cell adhesion molecule expression has been demonstrated by several groups (Styhanou, E , et al , J Biol.
  • the Type II IL-IR appears to be dispensable for IL-1 signaling and may act as a decoy receptor (Stylianou, E., et al , J Biol Chem 267:15836- 15841 (1992); Colotta, F., et al , Science 261 472-475 (1993); Sims, J.E., et al , Proc Natl Acad Sci USA 90:6155-6159 (1993)) While it appears clear that the Type I IL-IR is necessary for IL-1 signal transduction, it is uncertain if it is the only cell-surface molecule involved in IL-1 signaling.
  • Type I IL-IR is a single chain receptor (Curtis, B.M., et al , Proc Natl Acad Sci USA, 56:3045-3049 (1989)).
  • affinity cross-linking of IL-1 to cells expressing natural IL-1 receptor has yielded complex patterns of cross-linked proteins (Dower, et al , Cellular and
  • IL-IR accessory proteins Only two IL-IR accessory proteins are have been identified. Studies initiated to identify components of a potential IL-1 receptor complex suggest that there is a cell-surface protein in close association with the IL-IR that may play a role in IL-1 receptor binding and signaling.
  • a murine IL-1 receptor accessory protein (mulL-lR AcP) has been cloned and expressed (Greenfeder et al. J.
  • GenBank GenBank.
  • the reported sequence for this partial cDNA is 396 bp long and represents one of 1600 cDNAs that were sequenced from a library made to contain only expressed sequence tags.
  • the regions to overlap with the mulL-lR AcP sequence is nucleotides 893-1286 of the muIL-R AcP, which include the transmembrane domain.
  • IL-IR accessory molecule has a number of implications for IL-1 receptor biology.
  • mulL-lR AcM may not bind IL-1 directly
  • the accessory molecule forms a complex with the muType I IL-IR allowing
  • IL-l ⁇ to bind with higher affinity than the muType I IL-IR alone (Greenfeder, et al. J. Biol Chem, 270: 13757-13765 (1995)).
  • the presence or absence of the accessory molecule in different cell lines determined whether the low or the higher affinity site was detected, suggesting that the low affinity site corresponds to the muType I IL-IR alone, while the higher affinity site represents a complex of the muType I IL-IR with the mulL-lR AcM (Greenfeder, et al J Biol Chem, 270: 13757-13765 (1995)).
  • the IL-I R AcM would be analogous to affinity conversion and signal transduction subunits such as gp 130 in the IL-6 system (Hibi, M., et al , Cell 63.1 149-1 157 (1990)).
  • affinity conversion and signal transduction subunits such as gp 130 in the IL-6 system (Hibi, M., et al , Cell 63.1 149-1 157 (1990)).
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding the soluble IL-IR AcM polypeptide having the amino acid sequence is shown in Figure 1 [SEQ ID NO:2] or the amino acid sequence encoded by the cDNA clone deposited in a bacterial host as ATCC Deposit
  • the nucleotide sequence determined by sequencing the deposited IL-IR AcM clone which is shown in Figure 1 [SEQ ID NO:l], contains an open reading frame encoding a polypeptide of 356 amino acid residues, including an initiation codon at positions 303-305, with a leader sequence of about 17 amino acid residues, and a predicted molecular weight of about 42 kDa.
  • the amino acid sequence of the mature IL-I R AcM protein is shown in Figure 1 , amino acid residues 18-356 fSEQ ID NO:2].
  • one aspect of the invention provides an isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of : (a) a nucleotide sequence encoding the soluble IL-
  • IR AcM polypeptide having the complete amino acid sequence in Figure 1 [SEQ ID NO:2];
  • (b) a nucleotide sequence encoding the mature soluble IL-IR AcM polypeptide having the amino acid sequence at positions 18-356 in Figure 1 [SEQ ID NO:2];
  • (c) a nucleotide sequence encoding the soluble IL-IR AcM polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97666;
  • (e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c) or (d) above.
  • nucleic acid molecules that comprise a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical, to any of the nucleotide sequences in (a), (b), (c), (d) or (e), above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide in (a), (b), (c), (d) or (e), above.
  • This polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
  • An additional nucleic acid embodiment of the invention relates to an isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a IL-IR AcM polypeptide having an amino acid sequence in (a), (b), (c) or (d), above.
  • the present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such vectors and host cells and for using them for production of soluble IL-IR AcM polypeptides or peptides by recombinant techniques.
  • the invention further provides an isolated soluble IL-I R AcM polypeptide having amino acid sequence selected from the group consisting of: (a) the amino acid sequence of the soluble IL-IR AcM polypeptide having the complete 356 amino acid sequence, including the leader sequence shown in Figure 1 [SEQ ID NO:2]; (b) the amino acid sequence of the mature soluble IL- 1 R AcM polypeptide (without the leader) having the amino acid sequence at positions 18-356 in Figure 1 [SEQ ID NO:2]; (c) the amino acid sequence of the soluble IL-IR AcM polypeptide having the complete amino acid sequence, including the leader, encoded by the cDNA clone contained in ATCC Deposit No.
  • polypeptides of the present invention also include polypeptides having an amino acid sequence with at least 90% similarity, and more preferably at least 95% similarity to those described in (a), (b), (c) or (d) above, as well as polypeptides having an amino acid sequence at least 80% identical, more preferably at least 90% identical, and still more preferably 95%, 96%, 97%, 98% or 99% identical to those above.
  • An additional embodiment of this aspect of the invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a soluble IL-IR AcM polypeptide having an amino acid sequence described in (a), (b), (c) or (d), above.
  • Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a soluble IL- 1 R AcM polypeptide of the invention include portions of such polypeptides with at least six or seven, preferably at least nine, and more preferably at least about 30 amino acids to about 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the invention described above also are included in the invention.
  • the invention provides an isolated antibody that binds specifically to a soluble IL-IR AcM polypeptide having an amino acid sequence described in (a), (b), (c) or (d) above.
  • the soluble IL-IR AcM may not bind IL-1 directly, however, the accessory molecule forms a complex with the Type 1 IL-IR that binds IL-l ⁇ with higher affinity than the Type I IL-IR alone.
  • the presence or absence of the accessory molecule in different cell lines determines whether the low or the higher affinity site is detected suggesting that the low affinity site corresponds to the Type I IL-IR alone, while the higher affinity site represents a complex of the Type I IL-IR with the IL-IR AcM.
  • the present invention further provides a screening method for identifying IL-1 receptor agonists and antagonists, which involves: (a) providing a polypeptide comprising a type I IL-1 receptor and a polypeptide comprising IL-IR AcM or IL-IR AcM fragment, wherein IL-IR and IL-IR AcM or IL-IR and the IL-IR AcM fragment form a complex; (b) providing a candidate compound; (c) providing a polypeptide conprising IL-1 or a functional II- 1 fragment; and (d) determining the binding affinity of said complex for IL-1 whereby an increased binding affinity of said complex for IL-1 in the presence of said compound is indicative that said compound is an agonist for IL-1 signal transduction and a decreased binding affinity of said complex for IL-1 in the presence of said compound is indicative that said compound is an antagonist of IL-1 signal transduction.
  • Figure 1 shows the nucleotide [SEQ ID NO: 1] and deduced amino acid [SEQ ID NO:2] sequences of soluble IL-IR AcM.
  • the protein has a leader sequence of about 17 amino acid residues (underlined) and a deduced molecular weight of about 42 kDa.
  • the predicted amino acid sequence of the mature soluble IL-IR AcM protein is also shown in Figure 1 [SEQ ID NO:2].
  • Figures 2A and B shows the regions of similarity between the amino acid sequences of the soluble IL-IR AcM protein (HMEEJ22) and mouse interleukin 1 receptor accessory protein [SEQ ID NO:3] and between the amino acid sequences of the soluble IL-IR AcM protein (HMEEJ22) and the partial cDNA isolated from human infant brain (Adams, M.D.. et al.. Nature Genet. 4:373-380 (1993)) [SEQ ID NO:4].
  • Figure 3 shows an analysis of the IL-I R AcM amino acid sequence.
  • Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown.
  • the amino acid sequence of the IL-IR AcM protein is shown with the amino aicds that border each peak from the antigenic index plot displayed as underlined characters.
  • the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding soluble IL-IR AcM polypeptide, having the amino acid sequence shown in Figure 1 [SEQ ID NO:2], which was determined by sequencing a cloned cDNA.
  • the soluble IL-IR AcM protein of the present invention shares sequence homology with mouse interleukin 1 receptor accessory protein (Figure 2) [SEQ ID NO:3].
  • Figure 1 The nucleotide sequence shown in Figure 1 [SEQ ID NO: 1 ] was obtained by sequencing the HMEEJ22 clone, which was deposited on July 25, 1996 at the American Type Culture Collection, 12301 Park Lawn Drive, Rockville, Maryland 20852, and given accession number 97666.
  • isolated nucleic acid molecules which encode the soluble IL-IR AcM protein.
  • the IL-IR AcM is a novel member of the Ig superfamily.
  • nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art.
  • a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.
  • nucleotide sequence set forth herein is presented as a sequence of deoxyribonucleotides (abbreviated A, G , C and T).
  • nucleic acid molecule or polynucleotide a sequence of deoxyribonucleotides
  • RNA molecule or polynucleotide the corresponding sequence of ribonucleotides (A, G, C and U), where each thymidine deoxyribonucleotide (T) in the specified deoxyribonucleotide sequence is replaced by the ribonucleotide uridine (U).
  • RNA molecule having the sequence of SEQ ID NO:l set forth using deoxyribonucleotide abbreviations is intended to indicate an RNA molecule having a sequence in which each deoxyribonucleotide A, G or C of SEQ ID NO: 1 has been replaced by the corresponding ribonucleotide A, G or C, and each deoxyribonucleotide T has been replaced by a ribonucleotide U.
  • nucleic acid molecule of the present invention encoding a soluble IL-IR AcM polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material.
  • nucleic acid molecule described in Figure 1 [SEQ ID NO: 1] was discovered in a cDNA library derived from human microvascular endothelial cells.
  • the determined nucleotide sequence of the soluble IL-IR AcM cDNA of Figure 1 [SEQ ID NO: l] contains an open reading frame encoding a protein of 356 amino acid residues, with an initiation codon at positions 303-306 of the nucleotide sequence in Figure 1 [SEQ ID NO:l], a predicted leader sequence of about 17 amino acid residues, and a deduced molecular weight of about 42 kDa.
  • the amino acid sequence of the predicted mature soluble IL-IR AcM is shown in Figure 1 [SEQ ID NO:2] from amino acid residue 18 to residue 356.
  • the soluble IL-IR AcM protein shown in Figure 1 [SEQ ID NO:2] is about 94% similar and 85% identical to mouse interleukin 1 accessory protein ( Figure 2A).
  • the nucleotides 1060 to 1353 of soluble IL-IR AcM protein shown in Figure 1 [SEQ ID NO:2] is about 99% similar and 98% identical to the first 294 nucleotides partial cDNA isolated from human infant brain by Adams, M.D., et al, Nature Genet. 4:373-380 (1993) [SEQ ID NO:4]( Figure 2B).
  • the partial cDNA isolated by Adams was 396 nucleotides in length.
  • the actual soluble IL-IR AcM polypeptide encoded by the deposited cDNA comprises about 356 amino acids, but may be anywhere in the range of 345-370 amino acids; and the actual leader sequence of this protein is about 17 amino acids, but may be anywhere in the range of about 10 to about 20 amino acids.
  • nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically.
  • the DNA may be double-stranded or single-stranded.
  • Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non- coding strand, also referred to as the anti-sense strand.
  • isolated nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment
  • recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention.
  • DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution.
  • Isolated RNA molecules include in vivo or in vitro RNA transcripts of the DNA molecules of the present invention.
  • Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
  • Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) with an initiation codon at positions 303-306 of the nucleotide sequence shown in Figure 1 [SEQ ID NO:l]; DNA molecules comprising the coding sequence for the mature soluble IL-IR AcM protein shown in Figure 1 (last 339 amino acids) [SEQ ID NO:2]; and DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the soluble IL-IR AcM protein.
  • ORF open reading frame
  • SEQ ID NO:l DNA molecules comprising the coding sequence for the mature soluble IL-IR AcM protein shown in Figure 1 (last 339 amino acids) [SEQ ID NO:2]
  • the genetic code is well known in the art. Thus, it would be routine
  • the invention provides isolated nucleic acid molecules encoding the soluble IL-IR AcM polypeptide having an amino acid sequence encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 97666 on July 25, 1996.
  • this nucleic acid molecule will encode the mature polypeptide encoded by the above-described deposited cDNA clone.
  • the invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO: l ] or the nucleotide sequence of the soluble IL-IR AcM cDNA contained in the above-described deposited clone, or a nucleic acid molecule having a sequence complementary to one of the above sequences.
  • isolated molecules particularly DNA molecules, are useful as probes for gene mapping, by in situ hybridization with chromosomes, and for detecting expression of the soluble IL-I R AcM gene in human tissue, for instance, by Northern blot analysis.
  • the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA clone contained in ATCC Deposit 97666.
  • stringent hybridization conditions is intended overnight incubation at 42 °C in a solution comprising: 50%> formamide, 5x SSC (150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x
  • a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30-70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below.
  • polynucleotides hybridizing to a larger portion of the reference polynucleotide e.g., the deposited cDNA clone
  • a portion 50-750 nt in length, or even to the entire length of the reference polynucleotide are also useful as probes according to the present invention, as are polynucleotides corresponding to most, if not all, of the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 [SEQ ID NO:l].
  • such portions are useful diagnostically either as a probe according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by the polymerase chain reaction (PCR), as described, for instance, in Molecular Cloning, A
  • the hybridizing polynucleotides of the present invention could be generated synthetically according to known techniques.
  • a polynucleotide which hybridizes only to a poly A sequence such as the 3' terminal poly(A) tract of the soluble IL-IR AcM cDNA shown in Figure 1 [SEQ ID NO.T]), or to a complementary stretch of T (or U) resides, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).
  • the invention further provides isolated nucleic acid molecules comprising a polynucleotide encoding an epitope-bearing portion of the soluble IL- 1 R AcM protein.
  • isolated nucleic acid molecules are provided encoding polypeptides comprising the following amino acid residues in Figure 1 (SEQ ID NO:2), which the present inventors have determined are antigenic regions of the soluble IL-IR AcM protein: a. S18-M32: SDASERCDDWGLDTM (SEQ ID NO:5) b. V37-I45: VFEDEPARI (SEQ ID NO:6) c. G65-Y71 : GLTLIWY (SEQ ID NO: 7) d.
  • R74-I83 RQDRDLEEPI (SEQ ID NO: 8) e. L87-K96: LPENRISKEK (SEQ ID NO:9) f. S123-L129: SKVAFPL (SEQ ID NOTO) g. V132-P141 : VQKDSCFNSP (SEQ ID NO:l 1 ) h. V146-E152: VHKLYIE (SEQ ID NO: 12) i. I175-N189: ITWYMGCYKIQNFNN (SEQ ID NO: 13) j. LI 97-1204: LSFLIALI (SEQ ID NO: 14) k. H224-K232: HLTRTLTVK (SEQ ID NO: 15)
  • P248-E261 PNDHVVYEKEPGEE (SEQ ID NO: 16) m. I264-F272: IPCTVYFSF (SEQ ID NO: 17) n. D285-T293: DGKKPDDIT (SEQ ID NO: 18) o. I302-R312: ISHSRTEDETR (SEQ ID NO: 19) p. K320-K327: KVTSEDLK (SEQ ID NO: 20) q. S336-V347: SAKEGEVAKAAKV (SEQ ID NO: 21) r. 350-Q356: KGNRCGQ (SEQ ID NO: 22) Methods for generating such epitope-bearing portions of soluble IL-IR AcM are described in detail below.
  • nucleic acid molecules of the present invention which encode a soluble IL-IR AcM polypeptide may include, but are not limited to those encoding the amino acid sequence of the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as those encoding the about 17 amino acid leader or secretory sequence, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5' and 3 1 sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities.
  • the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide.
  • the marker amino acid sequence is a hexa-histidine peptide.
  • the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available.
  • hexa-histidine provides for convenient purification of the fusion protein.
  • the "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al, Cell 37: 767 (1984).
  • the present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the soluble IL-IR AcM protein.
  • Variants may occur naturally, such as a natural allelic variant.
  • allelic variant is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.
  • variants include those produced by nucleotide substitutions, deletions or additions.
  • the substitutions, deletions or additions may involve one or more nucleotides.
  • the variants may be altered in coding regoins, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the soluble IL-IR AcM protein or portions thereof. Also especially preferred in this regard are conservative substitutions.
  • nucleic acid molecules encoding the mature protein having the amino acid sequence shown in Figure 1 [SEQ ID NO:2] or the mature soluble IL-IR AcM amino acid sequence encoded by the deposited cDNA clone are highly preferred.
  • Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to (a) a nucleotide sequence encoding the full-length soluble IL-IR AcM polypeptide having the complete amino acid sequence in Figure 1 [SEQ ID NO:2], including the predicted leader sequence; (b) a nucleotide sequence encoding the mature soluble IL-IR AcM polypeptide (full-length polypeptide with the leader removed) having the amino acid sequence at positions 18-356 in Figure 1 [SEQ ID NO:2]; (c) a nucleotide sequence encoding the full-length
  • nucleotide sequence encoding the mature soluble IL-IR AcM polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97666; or (e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c) or (d).
  • a polynucleotide having a nucleotide sequence at least, for example,
  • nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the soluble IL-IR AcM polypeptide.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
  • These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
  • nucleotide sequence shown in Figure 1 or to the nucleotides sequence of the deposited cDNA clone can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711. Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2: 482-489 (1981), to find the best segment of homology between two sequences.
  • the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.
  • the present application is directed to nucleic acid molecules at least 90%, 95%o, 96%», 97%, 98% or 99% identical to the nucleic acid sequence shown in
  • Figure 1 [SEQ ID NO:l] or to the nucleic acid sequence of the deposited cDNA, irrespective of whether they encode a polypeptide having soluble IL-IR AcM activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having soluble IL-IR AcM activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer.
  • PCR polymerase chain reaction
  • nucleic acid molecules of the present invention that do not encode a polypeptide having soluble IL-IR AcM activity include, inter alia, (1) isolating the soluble IL-IR AcM gene or allelic variants thereof in a cDNA library; (2) in situ hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the soluble IL-IR AcM gene, as described in
  • nucleic acid molecules having sequences at least 90%), 95%), 97%, 98% or 99% identical to the nucleic acid sequence shown in
  • Figure 1 [SEQ ID NO:l] or to the nucleic acid sequence of the deposited cDNA which do, in fact, encode a polypeptide having soluble IL-IR AcM protein activity.
  • a polypeptide having soluble IL-I R AcM activity is intended polypeptides exhibiting activity similar, but not necessarily identical, to an activity of the soluble IL-IR AcM protein of the invention (either the full-length protein or, preferably, the mature protein), as measured in a particular biological assay.
  • Assays of IL-1 R AcM protein activity are well-known to those in the art. These assays can be used to measure IL-IR AcM protein activity of partially purified or purified native or recombinant protein. For example, an equilibrium and competitive binding studies using CHO stable cell lines
  • a CHO-IR/AcM cell line is established by simultaneous cotransfection of two expression vectors such that both IL-1 R and IL-IR AcM or a candidate IL-IR AcMare expressed at about a 1 :10 ratio of molecules/cell.
  • control cell lines which express only IL-IR or IL-IR AcM are also established.
  • CHO-dhfr cells are maintained in DMEM with 10% fetal bovine serum, 25mM HEPES, pH 7.0, 0.1 mML glutamine, IX HT supplement (0.1 mM hypoxanthine, 0.016 mM thymidine) (Boehringer Mannheim), 50 ⁇ g/ml gentamicin, IX penicillin/streptomycin/fungizone (JRH Biosciences).
  • Cells are transfected with pSV2-dhfr (Subramani, et al Mol. Cell. Biol.
  • each of the above generated cell lines are analyzed by equilibrium binding with 125 I- labeled IL-1 ⁇ .
  • Equilibrium binding of 12S I-labeled IL-1 to the cells can performed as described by Mizel, et al. J. Immunol. 138: 2906-2912 (1987).
  • 25 I labeling of IL-l ⁇ can be performed by methods well known to those skilled in the art, for example, as described by Chizzonite, et al. J. Immunol. 147:1548-1556 (1991).
  • the activity of the accessory protein, IL-IR AcM can be examined in the binding of IL-l ⁇ to a CHO-IR/AcM cell line obtained above. It is desirable for this cell line to express an excess amount of IL-IR AcM protein relative to IL- IR. Cell lines bearing only IL-IR AcM protein do not bind IL-l ⁇ and cell lines bearing only IL-R will bind IL-l ⁇ with low affinity (i.e., approximately K n 1.0-
  • a CHO-IR/AcM cell line, bearing both the IL-IR and IL-IR AcM results in IL-IR having a higher affinity binding site (i.e., approximately K D 0.02- 0.8 nM).
  • IL-1 R AcM activity can be monitored by testing whether the putative accessory protein interacts with the IL-IR so as to generate a high affinity IL-l ⁇ binding site.
  • the IL-IR AcM protein of the present invention can serve as a reference for the assay for IL-IR AcM activity associated with the high affinity IL-IR binding state.
  • a candidate polypeptide has IL-IR AcM activity by performing simple binding kinetics can be measured to determine receptor affinity for the ligand (i.e., IL- 1 ⁇ ).
  • Binding kinetic analysis experiments are well known to those skilled in the art (Chizzonite et al, Proc Natl. Acad. Sci. 56:8029-8033 (1989); Mizel, et al, J. Immunol. 735:2906-2912 (1987)).
  • the IL-IR AcM protein of the present invention can serve as a reference for the assay for IL-IR AcM activity associated with the high affinity IL- 1 R binding state.
  • a polypeptide having soluble IL-I R AcM protein activity includes polypeptides that exhibit IL-IR AcM activity, in the above-described assay. Although the degree of activity need not be identical to that of the IL-IR
  • a polypeptide having IL-I R AcM protein activity will exhibit substantially similar activity as compared to the IL-IR AcM protein (i.e., the candidate polypeptide will exhibit greater activity or not more than about tenfold less and, preferably, not more than about ten- old less activity relative to the reference IL-IR AcM protein).
  • nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence of the deposited cDNA or the nucleic acid sequence shown in Figure 1 [SEQ ID NO:l] will encode a polypeptide "having soluble IL-IR AcM protein activity.”
  • degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay.
  • nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having soluble IL-IR AcM protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid).
  • the present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of soluble IL-IR AcM polypeptides or fragments thereof by recombinant techniques.
  • Recombinant constructs may be introduced into host cells using well known techniques such infection, transduction, transfection, transvection, electroporation and transformation.
  • the vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
  • the polynucleotides may be joined to a vector containing a selectable marker for propagation in a host.
  • a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
  • vectors comprising cis-acting control regions to the polynucleotide of interest.
  • Appropriate trans-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.
  • the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.
  • Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adcnoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.
  • vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adcnoviruses, fowl pox viruses, pseudorabies viruses and retroviruses and vectors derived from combinations thereof, such as cosmids and phagemids.
  • the DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few.
  • an appropriate promoter such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few.
  • Other suitable promoters will be known to the skilled artisan.
  • the expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation.
  • the coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.
  • the expression vectors will preferably include at least one selectable marker.
  • markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria.
  • Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli,
  • Streptomyces and Salmonella typhimurium cells
  • fungal cells such as yeast cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS and Bowes melanoma cells
  • plant cells Appropriate culture mediums and conditions for the above-described host cells are known in the art.
  • vectors preferred for use in bacteria include pA2, pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.
  • preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia.
  • Other suitable vectors will be readily apparent to the skilled artisan.
  • bacterial promoters suitable for use in the present invention include the E. coli lacl and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters and the trp promoter.
  • Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid- mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al, Basic Methods In Molecular Biology (1986).
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type.
  • enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • secretion signals may be inco ⁇ orated into the expressed polypeptide.
  • the signals may be endogenous to the polypeptide or they may be heterologous signals.
  • the polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art.
  • a preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize receptors.
  • EP-A-O 464 533 (Canadian counte ⁇ art 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another human protein or part thereof.
  • the Fc part in fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232262).
  • Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations.
  • human proteins such as, shIL5- has been fused with Fc portions for the piupose of high- throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al., Journal of Molecular Recognition, Vol. 8 52-58 (1995) and K. Johanson et al., The Journal of Biological Chemistry, Vol. 270, No. 16, pp 9459-9471 (1995).
  • the soluble IL-IR AcM protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.
  • Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.
  • polypeptides of the present invention may be glycosylated or may be non-glycosylated.
  • polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.
  • the invention further provides an isolated soluble IL-IR AcM polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in Figure 1 [SEQ ID NO:2J, or a peptide or polypeptide comprising a portion of the above polypeptides.
  • peptide and oligopeptide are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least to amino acids coupled by peptidyl linkages.
  • polypeptide is used herein for chains containing more than ten amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus.
  • the invention further includes variations of the soluble IL-IR AcM polypeptide which show substantial soluble IL-IR AcM polypeptide activity or which include regions of soluble IL-IR AcM protein such as the protein portions discussed below.
  • Such mutants include deletions, insertions, inversions, repeats, and type substitutions (for example, substituting one hydrophilic residue for another, but not strongly hydrophilic for strongly hydrophobic as a rule). Small changes or such "neutral" amino acid substitutions will generally have little effect on activity.
  • polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified.
  • a recombinantly produced version of the soluble IL-IR AcM polypeptide can be substantially purified by the method described by Bradley, M.K. "Overexpressio of Proteins in Eukaryotes” Methods in Enzymology, Vol. 182.
  • polypeptides of the present invention include the polypeptide encoded by the deposited cDNA including the leader, the mature polypeptide encoded by the deposited the cDNA minus the leader (i.e., the mature protein), the polypeptide of Figure 1 [SEQ ID NO:2] including the leader, the polypeptide of Figure 1 [SEQ ID NO:2] minus the leader, as well as polypeptides which have at least 90%) similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 91%, 98% or 99% similarity to those described above.
  • polypeptides of the present invention include polypeptides at least 80% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%), 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA, to the polypeptide of Figure 1 [SEQ ID NO:2], and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.
  • % similarity for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive,
  • polypeptide having an amino acid sequence at least, for example,
  • a reference amino acid sequence of a soluble IL-IR AcM polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of the soluble IL-1 R AcM polypeptide.
  • up to 5%> of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
  • any particular polypeptide is at least 90%, 95%, 96%), 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in Figure 1 [SEQ ID NO:2J or to the amino acid sequence encoded by deposited cDNA clone can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 5371 1.
  • the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5%> of the total number of amino acid residues in the reference sequence are allowed.
  • polypeptide of the present invention could be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.
  • the polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies, which are useful in assays for detecting soluble IL-IR AcM protein expression as described below or as agonists and antagonists capable of enhancing or inhibiting soluble IL-IR AcM protein function.
  • polypeptides can be used in the yeast two- hybrid system to "capture" soluble IL-IR AcM protein binding proteins which are also candidate agonist and antagonist according to the present invention. The yeast two hybrid system is described in Fields and Song, Nature 340:245-246 (1989).
  • the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention.
  • the epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention.
  • An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule.
  • a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope.”
  • the number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen et al, Proc. Natl. Acad. Sci. USA 57:3998- 4002 (1983).
  • peptides or polypeptides bearing an antigenic epitope i.e., that contain a region of a protein molecule to which an antibody can bind
  • relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G., Shinnick, T. M., Green, N. and Learner, R.A. (1983) Antibodies that react with predetermined sites on proteins. Science 219:660-666.
  • Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, soluble peptides, especially those containing proline residues, usually are effective. Sutcliffe et al., supra, at 661.
  • 18 of 20 peptides designed according to these guidelines containing 8-39 residues covering 15% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.
  • Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention.
  • a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the native protein.
  • the antibodies raised by antigenic epitope-bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different peptides may be used for tracking the fate of various regions of a protein precursor which undergoes post-translational processing.
  • the peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (e.g., about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson et al. Cell 37:761-118 (1984) at 777.
  • the anti- peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adso ⁇ tion chromatography using methods well known in the art.
  • Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.
  • peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention also are considered epitope-bearing peptides or polypeptides of the invention and also are useful for inducing antibodies that react with the mimicked protein.
  • the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided); and sequences containing proline residues are particularly preferred.
  • Non-limiting examples of antigenic polypeptides or peptides that can be used to generate soluble IL-IR AcM-specific antibodies include the following: a. S 18-M32: SDASERCDDWGLDTM (SEQ ID NO:5) b. V37-I45: VFEDEPARI (SEQ ID NO:6) c. G65-Y71 : GLTLIWY (SEQ ID NO:7) d. R74-I83: RQDRDLEEPI (SEQ ID NO: 8) e. L87-K96: LPENRISKEK (SEQ ID NO:9) f. S123-L129: SKVAFPL (SEQ ID NO: 10) g.
  • V132-P141 VQKDSCFNSP (SEQ ID NO:l 1)
  • V146-E152 VHKLYIE (SEQ ID NO: 12)
  • I175-N189 ITWYMGCYKIQNFNN
  • L197-I204 LSFLIALI
  • H224-K232 HLTRTLTVK (SEQ ID NO: 15)
  • P248-E261 PNDHVVYEKEPGEE (SEQ ID NO: 16) m. I264-F272: IPCTVYFSF (SEQ ID NO: 17) n. D285-T293: DGKKPDDIT (SEQ ID NO: 18) o. I302-R312: ISHSRTEDETR (SEQ ID NO: 19) p. K320-K327: KVTSEDLK (SEQ ID NO: 20) q. S336-V347: SAKEGEVAKAAKV (SEQ ID NO: 21) r. K350-Q356: KGNRCGQ (SEQ ID NO: 22)
  • the epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, a short epitope-bearing amino acid sequence may be fused to a larger polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies. Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis.
  • Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment of the HA1 polypeptide which were prepared and characte ⁇ zed (by ELISA-type binding studies) in less than four weeks.
  • Houghten, R A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.
  • Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art See, for instance, Sutcliffe et al , supra; Wilson et al , supra. Chow, M et al , Proc Natl Acad Sci
  • animals may be immunized with free peptide, however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid
  • KLH keyhole limpet hemacyanin
  • peptides containing cysteine may be coupled to carrier using a linker such as m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde
  • Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intrape ⁇ toneal and/or intradermal injection of emulsions containing about 100 ⁇ g peptide or carrier protein and Freund'
  • the titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adso ⁇ tion to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.
  • Immunogenic epitope-bearing peptides of the invention i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance,
  • Geysen et al. discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen et al. with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the entire 213 amino acid sequence of the protein.
  • U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. et al. (1996) on
  • Peralkylated Oligopeptide Mixtures discloses linear C,-C 7 -alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest.
  • non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.
  • the present inventors believe that soluble IL-IR AcM is involved in IL-1 activity and that it forms a complex with the Type I IL- 1 R allowing IL- 1 ⁇ to bind with higher affinity than to the Type I IL-IR alone.
  • the presence or absence of the accessory molecule in different cell lines may determine whether the low or the high affinity site in the Type I IL-IR is formed.
  • the low affinity site corresponds to the Type I IL-IR alone, while the higher affinity site represents a complex of the Type I IL-IR with the IL-IR AcM.
  • IL-IR AcM may to be necessary for IL-1 signal transduction events and may to be required for the formation of a high affinity IL- 1 R binding state.
  • Stable cell lines established by simultaneous cotransfection of two expression vectors such that both IL-IR and IL-IR AcM are expressed at a 1 :10 ratio of molecules/cell and control cell lines which express only IL-IR or IL-IR AcM could be used in screening assays to identify potential agonists and antagonists for IL- 1.
  • the present invention further provides a screening method of identifying IL-1 receptor agonists, which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a type I IL-1 receptor and a polypeptide comprising IL-I R AcM or a IL-IR AcM fragment, wherein IL-IR and IL-IR AcM or an IL-IR AcM fragment form a complex; (b) administering a candidate agonist to said cell; and (c) determining the binding affinity of said complex for said candidate agonist relative to the binding of said comples for IL-1.
  • each of the cell lines are analyzed by equilibrium binding with 125 I-labeled IL-l ⁇ .
  • Equilibrium binding of 125 I-labeled IL-l ⁇ to the cells can performed as described by Mizel, et al. J. Immunol. 138: 2906-2912 (1987) and Greenfeder et al, J. Biol. Chem. 270:13757- 13765 (1995).
  • the activity of the candidate agonist can be examined relative to the binding of IL-l ⁇ to a CHO-IR/AcM cell line (as described, supra). It is desirable for this cell line to express an excess amount of
  • IL-IR AcM protein relative to IL-IR.
  • Cell lines bearing only IL-IR AcM protein will not bind IL-l ⁇ and cell lines bearing only IL-R bind IL-l ⁇ with low affinity (i.e., on the order of K D 1.0-3.3nM).
  • a CHO-IR/AcM cell line, bearing both the IL-IR and IL-IR AcM results in the IL-IR having a higher affinity binding site (i.e., on the order of K D 0.02-0.8 nM).
  • K D 0.02-0.8 nM affinity binding site
  • the invention provides a screening method of identifying an IL-1 signal transduction antagonist.
  • the results of Greenfeder, et al. (J. Biol. Chem, 270: 13757-13765 (1995)) suggest that the antagonist IL-lra prevents or disrupts formation of a complex between mulL-lR and mulL-lR AcP.
  • the screening method for identifying other antagonist of signal transduction which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a type I IL-1 receptor and a polypeptide comprising IL-IR AcM or an IL-1 R AcM fragment, wherein IL-IR and IL-IR AcM or IL-IR and the IL-IR AcM fragment form a complex; (b) administering a candidate antagonist to said cell; and (c) determining the whether said candidate antagonist disrupts or prevents formation of a complex between IL-IR and IL-IR AcM or IL-IR and the IL-IR AcM fragment.
  • IL-IR complex between IL-IR and IL-IR AcM
  • IL-l ⁇ cross-linked to IL-l ⁇ , IL-lra or the candidate antagonist.
  • an anti-type I IL-IR mAb or an anti-IL-lR AcM mAb a protein complex of > 200 kDa range will be observed for the cross linking reaction when IL-1 ⁇ is used as a ligand indicating formation of an IL-1 binding complex.
  • these antibodies will immunoprecipitate labeled IL 1 ⁇ .
  • the anti-IL-l R AcM mAb will not immunoprecipitate the labeled agonist. Rather, the anti-IL- 1 R AcM antibody will only precipitate an IL- 1 ra or a candidate antagonist complex in the 100- 120 kDa range indicating that the IL-IR and IL-IR AcM have not formed a complex.
  • the present invention further provides a screening method for identifying IL-1 receptor agonists and antagonists, which involves: (a) providing a polypeptide comprising a type I IL-1 receptor and a polypeptide comprising IL-
  • IR AcM or IL-IR AcM fragment wherein IL-1 R and IL-1 R AcM or IL-I R and the IL-IR AcM fragment form a complex; (b) providing a candidate compound; (c) providing a polypeptide conprising IL-1 or a functional IL-1 fragment; and (d) determining the binding affinity of said complex for I -1 whereby an increased binding affinity of said complex for IL- 1 in the presence of said compound is indicative that said compound is an agonist for IL-1 signal transduction and a decreased binding affinity of said complex for IL-1 in the presence of said compound is indicative that said compound is an antagonist of IL-1 signal transduction.
  • Candidate antagonists and agonist according to the present invention includelde IL-lra, polypeptides and antibodies that either enhance or inhibit formation of the IL-IR IL-IR AcM complex.
  • an antibody that inhibits the murine IL-1R-IL-1R accessory protein complex is described in Greenfeder, et al. J. Biol Chem, 270: 13757-13765 (1995).
  • antibodies directed against murine type I IL-1 receptors which block IL-1 activity are described in Chizzonite et al. Proc. Natl Acad Sci USA 56:8029 (1989); Lewis et al. Eur. J. Immunol. 20:201 (1990); Dinarello, Int. J. Clin. Lab. Res. 24:61-79
  • IL- 1 ra converts IL- 1 ra from an antagonist to a partial agonist of IL-1 activity in Ju et al. Proc. Natl. Acad. Sci USA 55:2658- 2662 (1991). Others have developed recombinant IL-1 mutants with altered activities (Dinarello Blood 77:1627-1652; Gehrke et al. J. Biol Chem. 265:5922- 5925 (1990)). Thus, methods are known in the art for developing candidate IL-
  • Administration of the candidate agonist or antagonist can be exogenous or endogenous and the candidate agonist or antagonist can be obtained from natural or recombinant sources.
  • the screening method further provides for host cells containing recombinant genes expressing IL-IR and IL- IR AcM, as described above.
  • a host cell containing recombinant genes is intended host cells which one or more of the recombinant constructs described herein have been introduced or a progeny of such host cells.
  • the invention provides antibodies directed to this accessory molecule which inhibit the interaction of IL-IR with IL-IR AcM thereby modulating IL-1 response of the cells.
  • These antibodies could be useful for immunoprecipitating cross-linked complexes for the antagonist screening assay as well as showing that the stable cell lines are in fact expressing the type I IL- 1 R and IL-IR AcM proteins. Methods for obtaining these antibodies are set forth below.
  • Soluble IL-IR AcM protein-specific antibodies for use in the present invention can be raised against the intact soluble IL-IR AcM protein or an antigenic polypeptide portion thereof, which may presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier.
  • a carrier protein such as an albumin
  • antibody As used herein, the term "antibody” (Ab) or “monoclonal antibody” (Mab) is meant to include intact molecules as well as antibody portions (such as, for example, Fab and F(ab') 2 portions) which are capable of specifically binding to soluble IL-1 R AcM protein. Fab and F(ab') 2 portions lack the Fc portion of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al, J. Nucl. Med. 24:316-325 (1983)). Thus, these portions are preferred.
  • the antibodies of the present invention may be prepared by any of a variety of methods.
  • cells expressing the soluble IL-IR AcM protein or an antigenic portion thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies.
  • a preparation of soluble IL-1 R AcM protein is prepared and purified as described above to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.
  • the antibodies of the present invention are monoclonal antibodies (or soluble IL-IR AcM protein binding portions thereof). Such monoclonal antibodies can be prepared using hybridoma technology
  • Such procedures involve immunizing an animal (preferably a mouse) with a soluble IL-IR AcM protein antigen or, more preferably, with a soluble IL-IR AcM protein-expressing cell. Suitable cells can be recognized by their capacity to bind soluble IL-IR AcM protein antibody.
  • Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 ⁇ g/l of nonessential amino acids, about 1 ,000 U/ml of penicillin, and about 100 ⁇ g/ml of streptomycin.
  • the splenocytes of such mice are extracted and fused with a suitable myeloma cell line.
  • Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP 2 O), available from the American Type Culture Collection, Rockville, Maryland.
  • the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gasiroenterology 50:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the soluble IL-IR AcM antigen.
  • additional antibodies capable of binding to the soluble IL- IR AcM protein antigen may be produced in a two-step procedure through the use of anti-idiotypic antibodies.
  • Such a method makes use of the fact that antibodies are themselves antigens, and therefore it is possible to obtain an antibody which binds to a second antibody.
  • soluble IL-IR AcM protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the soluble IL-IR AcM protein- specific antibody can be blocked by the soluble IL-I R AcM protein antigen.
  • Such antibodies comprise anti-idiotypic antibodies to the soluble IL-IR AcM protein-specific antibody and can be used to immunize an animal to induce formation of further soluble IL-IR AcM protein-specific antibodies.
  • Fab and F(ab') 2 and other portions of the antibodies of the present invention may be used according to the methods disclosed herein. Such portions are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab portions) or pepsin (to produce F(ab') 2 portions).
  • soluble IL-IR AcM protein-binding portions can be produced through the application of recombinant DNA technology or through synthetic chemistry. Where in vivo imaging is used to detect enhanced levels of soluble IL-1 R
  • chimeric monoclonal antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. See, for review, Morrison, Science 229: 1202 ( 1985); Oi et al, BioTechniques
  • suitable enzyme labels include malate dehydrogenase, staphylococcal nucleasc, delta-5- steroid isomerase, yeast-alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholine esterase.
  • radioisotopic labels examples include 3 H, '"In, l25 I, 13 I I, 32 P,
  • m In is a preferred isotope where in vivo imaging is used since its avoids the problem of dehalogenation of the 125 I or l3 l I-labeled monoclonal antibody by the liver.
  • this radionucleotide has a more favorable gamma emission energy for imaging (Perkins et al, Eur. J. Nucl Med. 70:296-301 (1985); Carasquillo et al, J. Nucl Med.
  • suitable non-radioactive isotopic labels include ,57 Gd, 55 Mn, ,62 Dy, 52 Tr, and 56 Fe.
  • suitable fluorescent labels include an 152 Eu label, a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an o-phthaldehyde label, and a fluorescamine label.
  • Suitable toxin labels include diphtheria toxin, ricin, and cholera toxin.
  • chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, and an aequorin label.
  • nuclear magnetic resonance contrasting agents include heavy metal nuclei such as Gd, Mn, and Fe.
  • Typical techniques for binding the above-described labels to antibodies are provided by Kennedy et al. (Clin. Chim. Ada 70: 1 -31 (1976)), and Schurs et al (Clin. Chim. Acta 57:1-40 (1977)). Coupling techniques mentioned in the latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method, all of which methods are inco ⁇ orated by reference herein.
  • the nucleic acid molecules of the present invention are also valuable for chromosome identification.
  • the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
  • mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.
  • the cDNA herein disclosed is used to clone genomic DNA of a soluble IL-IR AcM protein gene.
  • genomic DNA then is used for in situ chromosome mapping using well known techniques for this pu ⁇ ose.
  • some trial and error may be necessary to identify a genomic probe that gives a good in situ hybridization signal.
  • sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified portion. PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome.
  • mapping strategies that can similarly be used to map to its chromosome include in situ hybridization, prescreening with labeled flow- sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.
  • Fluorescence in situ hybridization of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step.
  • This technique can be used with probes from the cDNA as short as 50 or 60 bp.
  • Verma et al Human Chromosomes: A Manual Of Basic Techniques, Pergamon Press, New York (1988).
  • a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. This assumes 1 megabase mapping resolution and one gene per 20 kb.
  • IL-1 has an important role in modulating the proliferation, maturation, and functional activation of hematopoietic cells, including lymphoid and nonlymphoid cells. IL-1 may have an important function in the regulation liver metabolism and be responsible for some of the marked changes in hepatic protein synthesis that occur in the acute phase response to inflammation or tissue injury.
  • IL-1 is also involved in the regulation of bone remodulation, may be involved in the pathogenesis of chronic inflammatory joint diseases, such as rheumatoid arthritis, osteoarthritis, and may also play a role in the mechanisms of articular cartilage destruction hat occurs in degradative arthropathies.
  • Human IL-1 is capable of increasing collagen protein and mRNA levels in cultured normal human dermal fibroblasts, thus, IL-1 may have a role in the early stages of scleroderma and other fibrotic diseases.
  • IL-1 is capable of inducing a proliferative response in fibroblasts.
  • IL-1 may have important effects on vascular cells, including endothelial cells and vascular smooth muscle cells.
  • IL-1 may be involved in the pathogenesis of certain skin diseases, including chronic diseases such as psoriasis and epithelial fungus infections. IL-1 may have important effects on the functions of the hypothalamus-pituitary axis and thyroid gland. IL-1 has an important role in the regulation of insulin secretion by ⁇ cells in the pancreatic islets of Langerhans. Finally, IL-1 has important effects on the gonads and may play a role in the physiology of neural tissues. (Reviewed in Pimentel, Handbook of Growth Factors: Volume HI Hematopoietic Growth
  • IL-lra blocks the activity of exogenously administered IL-1 in a variety of animal models.
  • rabbits or baboons are injected with IL-1 they develope hypertension which is prevented by a prior injection of IL-lra (Ohlsson et al. Nature 348: 550 (1990); Fischer et al. Am. J. Physiol 261: R442 (1991)).
  • IL-IR blockade significantly reduces the severity of diseases, including those associated with infections, inflammation and metabolic disturbances (Arend, W.P. J. Clin. Invest 55:1445 (1991); Dinarello et al. Immunol Today 12: 404 (1991 )).
  • Table 1 of Dinarello, Int. J. Clin. Lab. Res. 24:61-79 (1994) (which is inco ⁇ orated herein by reference) different models are listed wherein a specific reduction in IL-IR activity has been employed to reduce the disease severity.
  • antibodies directed against IL-IR AcM are expected to behave as agonists or antagonist of IL-1 activity.
  • an antibody directed against the murine IL-I R accessory protein blocked the binding of IL-l ⁇ to murine type I IL-IR (Greenfeder et al. J. Biol. Chem, 270: 13757-13765 (1995)).
  • antibodies directed against the IL-IR AcM of the present invention that abrogate IL-1 activity can be used therapuetically to reduce the severity of diseases associated with IL-1.
  • the present invention is further directed antibody-based therapies which involve administering an anti-IL-lR AcM antibody to a mammalian, preferably human, patient for treating one or more of above-described disorders.
  • an anti-IL-lR AcM antibody to a mammalian, preferably human, patient for treating one or more of above-described disorders.
  • Methods for producing anti-IL-lR AcM polyclonal and monoclonal antibodies are described in detail above.
  • Such antibodies can may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.
  • a summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding IL-IR AcM locally or systemically in the body or by direct cytotoxicity of the antibody, e.g., as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below.
  • compositions of the present invention may be administered by any means that achieve their intended pu ⁇ ose.
  • Amounts and regimens for the administration of antibodies, their fragments or derivatives can be determined readily by those with ordinary skill in the clinical art of treating colon cancer and related disease.
  • administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes.
  • administration may be by the oral route.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concunent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • compositions within the scope of this invention include all compositions wherein the antibody, fragment or derivative is contained in an amount effective to achieve its intended pu ⁇ ose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
  • the effective dose is a function of the individual chimeric or monoclonal antibody, the presence and nature of a conjugated therapeutic agent (see below), the patient and his clinical status, and can vary from about 10 ⁇ g/kg body weight to about 5000 mg/kg body weight.
  • the preferred dosages comprise 0.1 to 500 mg/kg body wt.
  • the new pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the excipient.
  • preparations of an IL-IR AcM antibody or fragment of the present invention for parenteral administration such as in detectably labeled form for imaging or in a free or conjugated form for therapy, include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media, parenteral vehicles including sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, anti-oxidants. chelating agents, and inert gases and the like. See, generally, Remington's Pharmaceutical Science, 16th ed., Mack Publishing Co., Easton, PA, 1980.
  • the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing IL-IR AcM related disorders as described herein.
  • Such treatment comprises parenterally administering a single or multiple doses of the antibody, fragment or derivative, or a conjugate thereof.
  • the antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hemopoietic growth factors, etc., which serve to increase the number or activity of effector cells which interact with the antibodies. Since it appear to be necessary to block nearly all IL-lR's to block IL-I activity, it is prefened to use high affinity and/or potent in vivo IL-IR AcM-inhibiting and/or neutralizing antibodies, fragments or regions thereof, for both IL-IR AcM immunoassays and therapy of IL-1 related disorders.
  • Such antibodies, fragments, or regions will preferably have an affinity for human IL- IR AcM, expressed as Ka, of at least 10 8 M" 1 , more preferably, at least 10 9 M' 1 , such as 5 X 10 8 M '1 , 8 X 10 8 M "1 , 2 X 10 9 M ', 4 X 10 9 M 1 , 6 X 10 9 M 1 , 8 X 10 9
  • Preferred for human therapeutic use are high affinity murine and murine/human or human/human chimeric antibodies, and fragments, regions and derivatives having potent in vivo IL-1 -inhibiting and/or neutralizing activity, according to the present invention, e.g., that block IL-1 -induced IL-6 secretion, and mitogenic activity, in vivo, in situ, and in vitro.
  • Example I Expression and Purification of IL-IR AcM in E. coli
  • the DNA sequence encoding the mature soluble IL-IR AcM protein in the deposited cDNA clone is amplified using PCR oligonucleotide primers specific to the amino acid carboxyl terminal sequence of the soluble IL-1 R AcM protein and to vector sequences 3' to the gene. Additional nucleotides containing restriction sites BamHI and Sail to facilitate cloning are added to the 5' and 3' sequences, respectively.
  • the 5' oligonucleotide primer has the sequence 5' GGATCCATGACACTTCTGTGGTGTG 3' (SEQ ID NO:23) containing the underlined BamHI restriction site, followed by 16 nucleotides complementary to bp 1834-1853 of the antisense strand of the IL-IR AcM protein coding sequence set out in Figure 1 (SEQ ID NO: 1).
  • the 3* primer has the sequence 5' GTCGACTCACTGACCGCATCT 3'
  • the restrictions sites are convenient to restriction enzyme sites in the bacterial expression vector pQE-9, which is used for bacterial expression in these examples. (Qiagen, Chatsworth, CA, 9131 1).
  • the amplified IL-IR AcM protein DNA and the vector pQE-9 are both digested with BamHI and Sail and the digested DNAs are subsequently ligated together. Insertion of the IL-IR AcM protein DNA into the pQE-9 restricted vector places the IL-IR AcM protein coding region downstream of and operably linked to the vector's promoter and in-frame with an initiating AUG appropriately positioned for translation of IL-1 R AcM protein.
  • E. coli strain M15/rep4 containing multiple copies of the plasmid pREP4, which expresses lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described here.
  • Kanr lac repressor and confers kanamycin resistance
  • Transformants are identified by their ability to grow on LB plates in the presence of ampicillin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA is confirmed by restriction analysis.
  • Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin ( 100 ⁇ g/ml) and kanamycin (25 ⁇ g/ml).
  • the O/N culture is used to inoculate a large culture, at a dilution of approximately 1 : 100 to 1 :250.
  • the cells are grown to an optical density at 600 nm ("OD600”) of between 0.4 and 0.6.
  • Isopropyl-B-D-thiogalactopyranoside (“IPTG”) are then added to a final concentration of 1 mM to induce transcription from lac repressor sensitive promoters, by inactivating the lad repressor. Cells subsequently are incubated further for 3 to 4 hours.
  • Inclusion bodies are purified from the disrupted cells using routine collection techniques, and protein are solubilized from the inclusion bodies into 8M urea.
  • the 8M urea solution containing the solubilized protein is passed over a PD-10 column in 2X phosphate buffered saline ("PBS"), thereby removing the urea, exchanging the buffer and refolding the protein.
  • PBS 2X phosphate buffered saline
  • the protein is purified by a further step of chromatography to remove endotoxin. Then, it is sterile filtered.
  • the sterile filtered protein preparation is stored in 2X PBS at a concentration of 95 micrograms per mL.
  • vectors used for the transient expression of the IL-R AcM protein gene sequence in mammalian cells should carry the SV40 origin of replication. This allows the replication of the vector to high copy numbers in cells (e.g., COS cells) which express the T antigen required for the initiation of viral DNA synthesis. Any other mammalian cell line can also be utilized for this pu ⁇ ose.
  • a typical mammalian expression vector contains the promoter element, which mediates the initiation of transcription of mRNA, the protein coding sequence, and signals required for the termination of trancription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription can be achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV).
  • LTRs long terminal repeats
  • cellular signals can also be used (e.g., human actin promoter).
  • Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109).
  • Mammalian host cells that could be used include, human Hela, 283, H9 and Jurkart cells, mouse NIH3T3 and Cl 27 cells, Cos 1 , Cos 7 and CV 1 , African green monkey cells, quail QC1-3 cells, mouse L cells and Chinese hamster ovary cells.
  • the gene can be expressed in stable cell lines that contain the gene integrated into a chromosome.
  • a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.
  • the transfected gene can also be amplified to express large amounts of the encoded protein.
  • the DHFR dihydrofolate reductase
  • GS glutamine synthase
  • Another useful selection marker is the enzyme glutamine synthase (GS) (Mwphy et al, Biochem J. 227.277-279 ( 1991); Bebbington et al, Bio/Technology 70:169-175 (1992)).
  • GS glutamine synthase
  • the mammalian cells are grown in selective medium and the cells with the highest resistance are selected.
  • These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) cells are often used for the production of proteins.
  • the expression vectors pCl and pC4 contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al. , Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV -enhancer (Boshart et al,
  • the vectors contain in addition the 3 ' intron, the polyadenylation and termination signal of the rat preproinsulin gene.
  • the expression plasmid, pIL-lR AcM HA is made by cloning a cDNA encoding IL-R AcM into the expression vector pcDNAI/Amp (which can be obtained from Invitrogen, Inc.).
  • the expression vector pcDNAI/amp contains: ( 1 ) an E.coli origin of replication effective for propagation in E. coli and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eukaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron, and a polyadenylation signal arranged so that a cDNA conveniently can be placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker.
  • a DNA fragment encoding the IL- 1 R AcM protein and an HA tag fused in frame to its 3' end is cloned into the polylinker region of the vector so that recombinant protein expression is directed by the CMV promoter.
  • the HA tag corresponds to an epitope derived from the influenza hemagglutinin protein described by Wilson et al, Cell 37: 767 (1984). The fusion of the HA tag to the target protein allows easy detection of the recombinant protein with an antibody that recognizes the HA epitope.
  • the plasmid construction strategy is as follows
  • the IL-1 R AcM cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above regarding the construction of expression vectors for expression of IL-R AcM in E. coli.
  • one of the primers contains a hemagglutinin tag ("HA tag") as described above.
  • HA tag hemagglutinin tag
  • Suitable primers include the following, which are used in this example.
  • the 5' primer, containing the underlined BamHI site, an AUG start codon and 5 codons of the 5' coding region has the following sequence:
  • the 3' primer containing the underlined Xbal site, a stop codon, 9 codons thereafter forming the hemagglutinin HA tag, and 12 bp of 3' coding sequence (at the 3' end) has the following sequence:
  • the PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with BamHI and Xbal and then ligated.
  • the ligation mixture is transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies, Plasmid DNA is isolated from resistant colonies and examined by restriction analysis and gel sizing for the presence of the IL-IR AcM-encoding fragment.
  • COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook et al, Molecular Cloning: a Laboratory
  • Cells are incubated under conditions for expression of IL- 1 R AcM by the vector.
  • IL-IR AcM HA fusion protein Expression of the IL-IR AcM HA fusion protein is detected by radiolabelling and immunoprecipitation, using methods described in, for example
  • NP-40 0.1% SDS, l%NP-40, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson et al. cited above.
  • Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated proteins then are analyzed by SDS-PAGE gels and autoradiography. An expression product of the expected size is seen in the cell lysate, which is not seen in negative controls.
  • Plasmid pCl is a derivative of the plasmid pSV2-dhfr [ATCC Accession No. 37146]. Both plasmids contain the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary- or other cells lacking dihydrofolate activity that are transfected with these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate.
  • a selective medium alpha minus MEM, Life Technologies
  • MTX methotrexate
  • Plasmid pCl contains for the expression of the gene of interest a strong promoter of the long terminal repeat (LTR) of the Rouse Sarcoma Virus (Cullen, et al, Molecular and Cellular Biology, March 1985:438-4470) plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV) (Boshart et al, Cell 47:521-530, 1985). Downstream of the promoter are the following single restriction enzyme cleavage sites that allow the integration of the genes: BamHI, Pvull, and Nrul.
  • LTR long terminal repeat
  • CMV cytomegalovirus
  • the plasmid contains translational stop codons in all three reading frames followed by the 3' intron and the polyadenylation site of the rat preproinsulin gene.
  • Other high efficient promoters can also be used for the expression, e.g., the human ⁇ -actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLVI.
  • the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes can be used as well.
  • Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co-transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate.
  • the plasmid pCl is digested with the restriction enzyme BamHI and then dephosphorylated using calf intestinal phosphates by procedures known in the art.
  • the vector is then isolated from a 1% agarose gel.
  • the DNA sequence encoding IL-I R AcM, ATCC 97666, is amplified using PCR oligonucleotide primers corresponding to the 5 ' and 3 ' sequences of the gene: T h e 5 ' p r i m e r h a s t h e s e q u e n c e
  • the 3' primer has the sequence 5' Q ⁇ UCCTCACTGACCGCATCT 3' (SEQ ID NO:28) containing the EcoRI restriction followed by nucleotides complementary to the last 15 nucleotides of the IL-IR AcM coding sequence set out in Figure 1 (SEQ ID NO:l), including the stop codon.
  • amplified fragments are isolated from a 1% agarose gel as described above and then digested with the endonucleases BamHI and EcoRI and then purified again on a 1% agarose gel.
  • the isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase.
  • E. coli HBlOl cells are then transformed and bacteria identified that contained the plasmid pCl inserted in the correct orientation using the restriction enzyme BamHI. The sequence of the inserted gene is confirmed by DNA sequencing.
  • Chinese hamster ovary cells lacking an active DHFR enzyme are used for transfection.
  • 5 ⁇ g of the expression plasmid Cl are cotransfected with 0.5 ⁇ g of the plasmid pSVneo using the lipofecting method (Feigner et al, supra).
  • the plasmid pSV2-neo contains a dominant selectable marker, the gene neo from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418.
  • the cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418.
  • the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) and cultivated from 10-14 days. After this period, single clones are trypsinized and then seeded in 6-well petri dishes using different concentrations of methotrexate (25 nM, 50 nM, 100 nM, 200 nM, 400 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (500 nM, 1 ⁇ M, 2 ⁇ M, 5 ⁇ M). The same procedure is repeated until clones grow at a concentration of 100 ⁇ M.
  • Example 3 Cloning and expression of the Soluble IL-IR AcM protein in a baculovirus expression system
  • the cDNA sequence encoding the soluble IL-IR AcM protein in the deposited clone was amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene:
  • the 5' primer has the sequence 5 '
  • GACTGGATCCGCCATCATGACACTTCTGTGGTGTG 3' (SEQ ID NO:29) containing the underlined BamHI restriction enzyme site followed by 19 bases (bp 1834-1853) complementary to the antisense strand of the soluble IL-1 R AcM protein coding sequence of Figure 1 (SEQ ID NO: 1 ).
  • the 5' end of the amplified fragment encoding soluble IL-IR AcM protein receptor provides an efficient signal peptide.
  • An efficient signal for initiation of translation in eukaryotic cells as described by Kozak, M., J. Mol Biol. 796:947-950 (1987), may be located, as appropriate, in the vector portion of the construct.
  • the 3' primer has the full length sequence 5' GAC TGG TAG CCA TAG AAA TCA TGT GTA TAC C 3' (SEQ ID NO:30), containing the underlined Asp718 restriction followed by 25 nucleotides complementary to bp 2049-2070 of the sense strand of the soluble IL-1 R AcM protein set out in Figure 1 [SEQ ID NO: 1], and a stop codon.
  • the amplified fragment was isolated from a 1 % agarose gel using a commercially available kit ("Geneclean,” BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with BamHI and Asp718 and again is purified on a 1% agarose gel. This fragment is designated herein "F2".
  • the vector pA2 is used to express the soluble IL-1 R AcM protein in the baculovirus expression system, using standard methods, such as those described in Summers et al, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987).
  • This expression vector contains the strong polyhedrin promoter of the Autographa califomica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites.
  • AcMNPV Autographa califomica nuclear polyhedrosis virus
  • the beta- galactosidase gene from E. coli is inserted in the same orientation as the polyhedrin promoter and is followed by the polyadenylation signal of the polyhedrin gene.
  • the polyhedrin sequences are flanked at both sides by viral sequences for cellmediated homologous recombination with wild-type viral DNA to generate viable virus that express the cloned polynucleotide.
  • baculovirus vectors could be used in place of pA2, such as pAc373, pVL941 and pAcIMl provided, as those of skill readily will appreciate, that construction provides appropriately located signals for transcription, translation, trafficking and the like, such as an in-frame AUG and a signal peptide, as required.
  • Such vectors are described, for example, in Luckow et al, Virology 770:31-39 (1989). Suitable vectors will be readily apparent to the skilled artisan.
  • the plasmid was digested with the restriction enzymes BamHI and Asp718 and then was dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art.
  • the DNA was then isolated from a 1% agarose gel using a commercially available kit ("Gencclean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated herein "V2".
  • Fragment ⁇ 2 and the dephosphorylated plasmid V2 were ligated together with T4 DNA ligase.
  • E. coli HB 101 cells were transformed with ligation mix and spread on culture plates.
  • Bacteria were identified that contain the plasmid with the human soluble IL-IR AcM protein gene by digesting DNA from individual colonies using BamHI and Asp718 and then analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment was confirmed by DNA sequencing. This plasmid is designated herein as pA2HG 16302.
  • plasmid pA2HG16302 was co-transfected with 1.0 ⁇ g of a commercially available linearized baculovirus DNA ("BaculoGoldTM baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Feigner et al, Proc. Natl Acad. Sci. USA 54:7413-7417 (1987). 1 ⁇ g of a commercially available linearized baculovirus DNA ("BaculoGoldTM baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Feigner et al, Proc. Natl Acad. Sci. USA 54:7413-7417 (1987). 1 ⁇ g of
  • BaculoGoldTM virus DNA and 5 ⁇ g of the plasmid pA2HG 16302 were mixed in a sterile well of a microliter plate containing 50 ⁇ l of serum free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ⁇ l Lipofectin plus 90 ⁇ l Grace's medium were added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture was added drop- wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with I ml Grace's medium without serum. The plate was rocked back and forth to mix the newly added solution. The plate is then incubated for 5 hours at 27 °C. After 5 hours the transfection solution was removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. The plate is put back into an incubator and cultivation is continued at 27 °C for four days.
  • serum free Grace's medium Life Technologies Inc.
  • plaque assay After four days the supernatant was collected and a plaque assay was performed, as described by Summers and Smith, supra.
  • An agarose gel with "Blue Gal” (Life Technologies Inc., Gaithersburg, MD) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques.
  • a detailed description of a "plaque assay” of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, MD, at pages 9-10.
  • Sf9 cells are grown in Grace's medium supplemented with 10% heat- inactivated FBS.
  • the cells are infected with the recombinant baculovirus A2HG16302 at a multiplicity of infection ("MOI") of about 2 (about 1 to about
  • Northern blot analysis is carried out to examine the levels of expression of the gene encoding the IL-IR AcM protein in human tissues, using methods described by, among others, Sambrook et al, cited above.
  • a cDNA probe containing the entire nucleotide sequence of the IL- 1 R AcM protein of the present invention (SEQ ID NO: 1 ) is labeled with "P using the redip ⁇ meTM DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labelling, the probe was purified using a CHROMA SPIN- 100TM column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labelled probe is then used to examine various human tissues for the expression of the gene encoding the IL- 1 R AcM protein.
  • MTN Multiple Tissue Northern
  • H human tissues
  • IM human immune system tissues
  • ADDRESSEE STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
  • ACTAGAACAT CAGCAGGCCC TTAGAAGCCT CACTCTTGCC CCTCCCTTTA ATATCTCAAA 300
  • GCT GGC CTT ACT CTG ATC TGG TAT TGG ACT AAG CAG
  • GAC CGG GAC CTT 539 Ala Gly Leu Thr Leu lie Trp Tyr Trp Thr Lys Gin Asp Arg Asp Leu 50 55 60
  • TGT CCA AAT GTA GAT GGA TAT TTT CCT TCC AGT GTC AAA CCG ACT ATC 827 Cys Pro Asn Val Asp Gly Tyr Phe Pro Ser Ser Val Lys Pro Thr lie 145 150 155
  • AAATATTCAA AGCTACCAAA GATAGAAAAA ACTGGTAGAG CCACATATTG TTGGTGAATT 1710
  • Trp Tyr Met Gly Cys Tyr Lys He Gin Asn Phe Asn Asn Val He Pro 160 165 170 175
  • MOLECULE TYPE cDNA
  • the applicant hereby request that, until the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.
  • the request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the pbulic under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Norwegian Patent office or any person approved by the applicant in the individual case.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention porte sur une nouvelle protéine moléculaire accessoire, soluble, du récepteur d'IL-1 (IL-1R AcM) qui est un membre de la superfamille d'Ig. L'invention porte notamment sur des molécules d'acide nucléique isolées codant la protéine humaine IL-1R AcM; sur des polypeptides d'Il-1R AcM ainsi que sur des vecteurs, des cellules hôtes et des méthodes de recombinaison visant à produire ces molécules. Des procédés de criblage permettent également d'identifier l'agoniste et les antagonistes de la transduction du signal IL-1. L'invention porte également sur des procédés de traitement d'états physiologiques et pathologiques utilisant les antagonistes d'IL-1R AcM.
PCT/US1996/013954 1996-08-26 1996-08-26 Molecule accessoire soluble du recepteur de l'interleukine 1 WO1998008969A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU70116/96A AU7011696A (en) 1996-08-26 1996-08-26 Soluble interleukin-1 receptor accessory molecule
PCT/US1996/013954 WO1998008969A1 (fr) 1996-08-26 1996-08-26 Molecule accessoire soluble du recepteur de l'interleukine 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/013954 WO1998008969A1 (fr) 1996-08-26 1996-08-26 Molecule accessoire soluble du recepteur de l'interleukine 1

Publications (1)

Publication Number Publication Date
WO1998008969A1 true WO1998008969A1 (fr) 1998-03-05

Family

ID=22255698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013954 WO1998008969A1 (fr) 1996-08-26 1996-08-26 Molecule accessoire soluble du recepteur de l'interleukine 1

Country Status (2)

Country Link
AU (1) AU7011696A (fr)
WO (1) WO1998008969A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229047A3 (fr) * 1998-09-25 2002-10-02 Regeneron Pharmaceuticals, Inc. Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
US6733753B2 (en) 1997-02-10 2004-05-11 Amgen Inc. Composition and method for treating inflammatory diseases
US7619066B2 (en) 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
WO2014100772A1 (fr) * 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Anticorps qui se fixent à il1 rap lié à la membrane
US11168140B2 (en) 2018-08-17 2021-11-09 23Andme, Inc. Anti-IL1RAP antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023067A1 (fr) * 1995-01-23 1996-08-01 F.Hoffmann-La Roche Ag Proteine accessoire humaine du recepteur de l'interleukine-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023067A1 (fr) * 1995-01-23 1996-08-01 F.Hoffmann-La Roche Ag Proteine accessoire humaine du recepteur de l'interleukine-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EST-STS ON MASPAR SEARCH, WashU-Merck EST Project (St Louis MO, USA), No. T70863, HILLIER et al., "yd15f12.rl Homo Sapiens cDNA Clone 108335 5", 15 March 1995. *
DATABASE EST-STS ON MASPAR SEARCH, WashU-Merk EST Project (St Louis MO, USA), No. H80590, HILLIER et al., "yu76e04.rl Homo Sapiens cDNA Clone 239742 5", 09 November 1995. *
DATABASE ETS-STS ON MASPAR SEARCH, WashU-Merck EST Project (St Louis MO, USA), No. T85756, HILLIER et al., "yd60e03.rl Homo Sapiens cDNA Clone 112636 5", 17 March 1995. *
FEBS LETTERS, 05 February 1996, Vol. 391, WESCHE et al., "Co-Expression of mRNA for Type I and Type II Interleukine 1 Receptors and the IL-1 Receptor Accessory Protein Correlates to IL-1 Responsiveness", pages 105-106. *
J. BIOL. SCI., 09 June 1995, Vol. 270, No. 23, GREENFELDER et al., "Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex", pages 13757-13765. *
J. NEUROIMMUNO., May 1996, Vol. 66, LIU et al., "Rat Homolog of Mouse Interleukin-1 Receptor Accessory Protein: Cloning, Localization and Modulation Studies", pages 42-44. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733753B2 (en) 1997-02-10 2004-05-11 Amgen Inc. Composition and method for treating inflammatory diseases
EP1229047A3 (fr) * 1998-09-25 2002-10-02 Regeneron Pharmaceuticals, Inc. Protéines de fusion du récepteur de IL-1 utilisées comme antagonistes et méthodes d'utilisation et de fabrication
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
WO2002095414A1 (fr) * 2001-05-18 2002-11-28 Warner-Lambert Company Llc Procedes de criblage d'un complexe trimoleculaire d'interleukines solubles
US7619066B2 (en) 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
US10765747B2 (en) 2004-04-02 2020-09-08 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
WO2014100772A1 (fr) * 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Anticorps qui se fixent à il1 rap lié à la membrane
US11168140B2 (en) 2018-08-17 2021-11-09 23Andme, Inc. Anti-IL1RAP antibodies
US12304959B2 (en) 2018-08-17 2025-05-20 23Andme, Inc. Method of treating asthma with anti-IL1RAP antibodies

Also Published As

Publication number Publication date
AU7011696A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
EP0961831B1 (fr) Endokine alpha humaine
US20080261252A1 (en) Soluble Interleukin-1 Receptor Accessory Molecule
US6521742B2 (en) Human endokine alpha
WO1998012344A1 (fr) Genes de type recepteurs du facteur de necrose tumorale humain
WO1998011138A1 (fr) Chimiokine alpha-4
EP0963205A1 (fr) Ligand ii du type recepteur de t1
WO1998008969A1 (fr) Molecule accessoire soluble du recepteur de l'interleukine 1
US6232100B1 (en) Cortistatin Polypeptides
US6667032B2 (en) T1 receptor-like ligand II polypeptides
US20040138443A1 (en) T1-R ligand III
EP0990000A1 (fr) Facteur de croissance 3 du tissu conjonctif
WO1998029438A9 (fr) Polypeptides de cortistatine
US6576445B1 (en) Chemokine α-4
US8110659B1 (en) Human tumor necrosis factor receptor-like genes
AU716100B2 (en) Human vascular endothelial growth factor 3
US20020132304A1 (en) Human parotid secretory protein
EP0958374A1 (fr) Ligand i du type recepteur de t1
US20030129643A1 (en) T1 receptor-like ligand I
NZ514393A (en) Use of antibodies that bind to the endokine alpha polypeptide so as to decrease the level of endokine alpha activity in situ
NZ505148A (en) Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
JP2004041216A (ja) ヒトエンドカインα

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BG BR BY CA CN CZ EE FI GE HU IL JP KG KP KR KZ LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM TR UA US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98511588

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA